VT3989, Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma

Latest Data from Phase I/II Study Reported in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025 and Published Concurrently in Nature Medicine VT3989 Achieves 32% Overall Response Rate, 86% Disease Control Rate, and 40 Weeks of Median Progression-Free...